+patients served
Named Patient Programs, also referred to as compassionate use programs or expanded access programs, play a pivotal role in providing access to potentially life-saving medications for patients who are facing serious or life-threatening conditions. These programs are designed to bridge the gap between the development of new medications and their regulatory approval, ensuring that patients in need have access to innovative treatments before they are widely available on the market.
Operated by pharmaceutical companies, Named Patient Programs operate on a case-by-case basis, allowing eligible patients to receive investigational drugs outside of the confines of traditional clinical trials. This can be particularly beneficial for patients who may not meet the criteria for participation in clinical trials or who have exhausted all approved treatment options.
Through Named Patient Programs, patients can gain access to promising new therapies that have not yet received regulatory approval in their country. This can provide a ray of hope for patients who are facing limited treatment options and may offer a chance for improved outcomes and quality of life.
In addition to providing access to investigational drugs, Named Patient Programs also facilitate the provision of unlicensed medicines and unregistered medicines, which have not yet undergone formal regulatory approval processes but may still hold potential benefits for patients in need. These programs serve as a lifeline for individuals who require access to treatments that are not available through conventional channels, offering hope and the possibility of improved health outcomes.
